Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Madmanmadoxon Jul 03, 2018 12:47pm

172 Views

Post# 28262809

RE:RE:Secondary Endpoints = Investment Further De-Risked

I for one am going to be very interested to see just how low ATB346 dosage can go and still maintain its effectiveness in its primary purpose relative to placebo's and/or standard Naproxen dose. I think it will be challenging yet excting to model since the duration ATB346 stays in the body is likely not similar to the Naproxen profile benchmark.

What will be the optimal dosage that maximizes pain reduction whilst maintaining/ensuring the superior safety profile demonstrated in the data. :)

Bullboard Posts

Thesis Gold makes high-grade discovery at Ring Zone